Dermatology

SYSA1902 Biosimilar Proves Equivalent to Reference Ustekinumab in Plaque Psoriasis

September 8th 2025

By Skylar Jeremias

A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque psoriasis, expanding patient options.

Japanese Trial Supports Widespread Use, Safety of Infliximab Biosimilar Use

September 4th 2025

By Skylar Jeremias

Article

A recent Japanese study confirms that switching from originator infliximab to biosimilars maintains remission in patients who have rheumatoid arthritis, enhancing treatment accessibility.

Biosimilar Business Recap: Updates on Tocilizumab, Omalizumab, and Ranibizumab Products

August 13th 2025

By Skylar Jeremias

Article

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ranibizumab.

Real-World Data Suggest Long-Term Safety of CT-P13 in IBD, RA

July 2nd 2025

By Deana Ferreri, PhD

Article

The MEGA-J study reveals CT-P13's long-term safety and effectiveness in treating inflammatory bowel disease and rheumatoid arthritis, with minimal adverse reactions.

Adalimumab Double Take: The Unexpected Return to Reference Humira

June 30th 2025

By Skylar Jeremias

Article

About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26th 2025

By Skylar Jeremias

Article

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in Europe and Latin America.

FDA Approves Steqeyma for Children With Plaque Psoriasis, Psoriatic Arthritis

June 17th 2025

By Skylar Jeremias

Article

Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children with chronic inflammatory conditions.

Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan

June 17th 2025

By Skylar Jeremias

Article

Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.

New Data Support Hulio as an Interchangeable Adalimumab Option

June 16th 2025

By Skylar Jeremias

Article

The new data were collected to fulfill the FDA's requirements to designate adalimumab-fkjp (Hulio) as interchangeable with Humira, enhancing access to affordable biologics for chronic plaque psoriasis treatment.

Biosimilar FYB202 Shows Therapeutic Equivalence to Ustekinumab for Plaque Psoriasis

June 12th 2025

By Cameron Santoro

Article

Switching from reference ustekinumab to biosimilar FYB202 maintained comparable efficacy, safety, and immunogenicity in patients with moderate to severe plaque psoriasis.